Beam Therapeutics Inc. (BEAM) — Analyst outlook / Analyst consensus target is. Based on 27 analyst ratings, the consensus is bullish — 18 Buy, 8 Hold, 1 Sell.
The consensus price target is $40.86 (low: $26.00, high: $74.00), representing an upside of 34.9% from the current price $30.30.
Analysts estimate Earnings Per Share (EPS) of $-4.69 and revenue of $0.05B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-4.58 vs est $-4.68 (beat +2.2%). 2025: actual $-0.81 vs est $-4.22 (beat +80.8%). Analyst accuracy: 0%.
BEAM Stock — 12-Month Price Forecast
$40.86
▲ +34.85% Upside
Average Price Target
Based on 27 Wall Street analysts offering 12-month price targets for Beam Therapeutics Inc., the average price target is $40.86, with a high forecast of $74.00, and a low forecast of $26.00.
The average price target represents a +34.85% change from the last price of $30.30.
Highest Price Target
$74.00
Average Price Target
$40.86
Lowest Price Target
$26.00
BEAM Analyst Ratings
Buy
Based on 27 analysts giving stock ratings to Beam Therapeutics Inc. in the past 3 months
EPS Estimates — BEAM
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$4.58
vs Est –$4.68
▲ 2.3% off
2025
Actual –$0.81
vs Est –$4.22
▲ 421.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — BEAM
53%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.064B
vs Est $0.051B
▲ 19.1% off
2025
Actual $0.140B
vs Est $0.036B
▲ 74.2% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
